Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY01612 vs CAELYX in Advanced Breast Cancer
NCT06098599Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY01612 in breast cancer (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Plasma Maximum Concentration (Cmax) of Encapsulated Doxorubicin at Day 56, Area Under Plasma Concentration-Time Curve of Encapsulated Doxorubicin at Day 56 and 2 more. Started May 2022; status: completed.
02
Drugs
LY01612
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06098599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098599.